(Q38525874)

3 September 2017

1 reference

title

Pathogenesis of Behçet's disease: autoinflammatory features and beyond (English)

1 reference

3 September 2017

0 references

Ahmet Gül

1

1 reference

3 September 2017

12 June 2015

1 reference

Seminars in Immunopathology

3 September 2017

1 reference

3 September 2017

37

1 reference

3 September 2017

4

1 reference

3 September 2017

413-418

1 reference

https://scigraph.springernature.com/pub.10.1007/s00281-015-0502-8

3 September 2017

0 references

cites work

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Behçet's disease as an autoinflammatory disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

A proposed classification of the immunological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Autoinflammatory disease reloaded: a clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

IL-1 blockade in autoinflammatory syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Autoinflammatory gene mutations in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Familial aggregation of Behçet's disease in Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

HLA-B*51 and Behçet Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Relationships of HLA-B51 or B5 genotype with Behcet's disease clinical characteristics: systematic review and meta-analyses of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Genetics of Behçet's disease: lessons learned from genomewide association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Behçet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Rationally designed inhibitor targeting antigen-trimming aminopeptidases enhances antigen presentation and cytotoxic T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Comparative study of the skin pathergy test with blunt and sharp needles in Behçet's disease: confirmed specificity but decreased sensitivity with sharp needles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Response to intradermal injection of monosodium urate crystals in Behçet's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Neutrophilic dermatoses: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Tocilizumab for severe refractory neuro-Behçet: three cases IL-6 blockade in neuro-Behçet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Lack of efficacy of tocilizumab in mucocutaneous Behcet's syndrome: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

T-bet expression is upregulated in active Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Excessive expression of Txk, a member of the Tec family of tyrosine kinases, contributes to excessive Th1 cytokine production by T lymphocytes in patients with Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Identification of multiple independent susceptibility loci in the HLA region in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Apremilast for Behçet’s Syndrome — A Phase 2, Placebo-Controlled Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0502-8

Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease

21 January 2018

1 reference

12 December 2020

Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study

1 reference

12 December 2020

Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials

1 reference

12 December 2020

1 reference

12 December 2020

On relapsing, aphthous ulcers of the mouth, eye and genitalia caused by a virus. 1937.

1 reference

12 December 2020

Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review

1 reference

12 December 2020

Peripheral blood T cell expansions in patients with Behcet's disease

1 reference

12 December 2020

Immunohistology of skin pathergy reaction in Behçet's disease.

1 reference

12 December 2020

Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects.

1 reference

12 December 2020

Behçet's disease and other autoinflammatory conditions: what's in a name?

1 reference

12 December 2020

Up-regulation of Th17 and related cytokines in Behçet's disease corresponding to disease activity.

1 reference

12 December 2020

Behçet's disease: an update on the pathogenesis

1 reference

12 December 2020

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

1 reference

12 December 2020

Anti-cytokine biologic treatment beyond anti-TNF in Behçet's disease.

1 reference

12 December 2020

Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab

1 reference

12 December 2020

Genome-wide association studies in Behçet's disease: expectations and promises

1 reference

12 December 2020

Lack of association of HLA-B*51 with a severe disease course in Behçet's disease

1 reference

12 December 2020

10.1007/S00281-015-0502-8

Identifiers

DOI

1 reference

PubMed ID

26068404

Dimensions Publication ID

3 September 2017

0 references

1 reference

PubMed ID

26068404